anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides cancer treating medicine which is a natural Chinese herb medicine preparation through more than ten years of research and clinical observation with the combination of a Chinese medicine theory. The cancer treating medicine mainly nourishes bodies and assists to attack cancer. The cancer treating medicine has the functions of relieving livers, regulating qi, stimulate blood circulation, removing blood stasis, clearing heat, cooling blood, removing inflammation, stopping pain, removing tumescence, stopping blood, moistening dryness, relaxing bowels, removing poison, promoting intelligence, relieving sore throats, moistening lungs, etc., and does not have a side effect. The present invention has good treating effects on various cancers such as lung cancers, liver cancers, gastric cancers, rectum cancers, mammary cancers, etc., and is favorable by matching postoperative therapy. Compared with a similar product, the cancer treating medicine largely shortens a treating course and has fast effects. The total effective rate of the cancer treating medicine achieves more than 80%. The cancer treating medicine is reviewed favourably by local patients. Therefore, the cancer treating medicine has development value.
This article reveals the binding mechanism between glycyrrhizic acid (GA) and α-synuclein to may provide further information for the modulation of synucleinopathies using bioactive compounds. Therefore, the inhibitory activities of GA against α-synuclein aggregation and induced neurotoxicity were evaluated using different assays. Results showed that α-synuclein-GA binding was mediated by intermolecular hydrogen bonds leading to the formation of a slightly folded complex. Theoretical studies revealed that GA binds to the N-terminal domain of α-synuclein and triggers a compact structure around a major part of the N-terminal and the NAC regions along with fluctuations in the C-terminal domain, which are prerequisites for the inhibition of α-synuclein aggregation. Then, the cellular assays showed that GA as a potential small molecule can inhibit the oligomerization of α-synuclein and relevant neurotoxicity through modulation of neural viability, membrane leakage, and ROS formation in a concentration-dependent manner. As a result, the primary mechanism of GA's anti-aggregation and neuroprotective activities is the reorganized α-synuclein structure and fluctuating C-terminal domain, which promotes long-range transient intramolecular contacts between the N-terminal and the C-terminal domain.
The treatment program consists of 12 modules that are offered during 12 weeks on Internet. Modules consist of parental education, psycho-education for the children, exposure, cognitive restructuring and home exercises. A psychologist guides parents and children through the treatment with continuous contact using the message function on the Internet platform that is used.
Psychosis is a serious mental condition in which a person momentarily loses contact with reality. People in a state of psychosis may experience hallucinations or delusional beliefs that make day-to-day functioning difficult. During the early development of psychosis, people undergo an initial change in mood, thinking, or behavior that may include making mistakes about smells, sounds, or sights; becoming easily distracted; and developing suspicions of others. These basic symptoms can be early warning signs of a brain disorder, including anxiety disorder, depression, or psychotic disorder. Basic symptoms may be due to a number of factors, including a reaction to stress or drugs or just a part of normal adolescence. To identify psychosis early and accurately, more information is needed on the initial stages, biological markers, and progression of psychosis. This study will gather information on the natural history of the basic symptoms of psychosis to identify factors that may affect the improvement or persistence of the symptoms.

Participation in this study will last up to 5 years. The initial screening visit will be used to determine whether a participant is eligible for the group displaying basic symptoms or the control group. Initial screening will include giving a blood sample for routine lab tests, a physical exam, a drug test, and questions about medical history and symptoms. All participants will then partake in baseline evaluations, which involve assessments concerning concentration, problem solving, memory, social skills, and ability to identify smells. Participants will also respond to questions about symptoms, school and social functioning, stressful situations, and family history of illnesses. The participants who meet the criteria for basic symptoms will attend monthly 1-hour follow-up visits for the first year of the study. During these visits, participants will be asked about the status of their basic symptoms and use of medications. For the second year of the study, follow-up visits will occur every 2 months, and for the third, fourth, and fifth years of the study, visits will be every 3 months. Repeat baseline assessments will occur every 6 months, with each assessment visit lasting about 5 hours. All participants will undergo endpoint evaluations that follow the same format as most baseline assessments. Participants who develop a psychotic disorder during the study will attend an additional follow-up visit 6 months after the endpoint evaluation to confirm diagnosis. Participants who decide that they no longer wish to attend regular study visits may be asked to participate in follow-up telephone interviews about their basic symptoms every 6 months.
The oral antihistamine condition will consist of fexofenadine (540mg) and famotidine (40mg). Commercially available pills (3 x 180mg fexofenadine and 2 x 20mg famotidine) will be placed within opaque capsules and administered to the participants upon arrival to the laboratory.
PURPOSE:To provide a skin-beautifying agent containing homocysteine, etc., and hinokitiol as main active components, exhibiting inhibitive action at the formation of melanin pigment at a small amount compared with separate use of the components by synergistic effect, having excellnet stability and giving excellent skin-beautifying effect. CONSTITUTION:The objective agent contains hinokitiol and one or more compounds selected from homocysteine of formula C4H9NO2S, cysteine, ascorbic acid and their esters as main active components. The content of e.g. homocysteine or its ester is >=10mumol/1 and that of hinokitiol is >=40mumol/1. The main active components are mixed in cream, pack, lotion, etc. The formation of melanin pigment is suppressed to prevent the blackening of the skin. The product has high marketability.
Patellofemoral Pain Syndrome is one of the most common musculoskeletal problem in the world. It's incidence is also becoming higher and most people who have knee pain suffer from it for long time. In the treatment of PFPS, conservative treatment methods are preferred prior to surgical ones. When the literature was reviewed, no study in which Mobilization with movement (MWM) method was used and in which the effects of it was shown and compared with (Kinesiotaping) KT has been found so far with respect to the treatment of PFPS. Thirty-five female patients diagnosed with unilateral PFPS were randomly assigned into 2 groups. The patients in the first group (n=18) received two techniques of Mobilization with movement intervention while Kinesiotaping was applied to the other group (n=17). Both groups were treated with exercise. All patients received 4 sessions of treatment twice a week for a period of 2 weeks and followed up in accordance with a 6-week-home exercise program. Primary outcomes: pain severity, knee range of motion, hamstring flexibility, and physical performance (10-step stair climbing test, timed up and go test), Kujala Patellofemoral Pain Scoring and Y-Balance test were assessed.
Electrospray systems and modified electrospray systems for the fabrication of core-shell particles for controlled-release and/or sustained-release treatment and delivery are herein disclosed. The electrospray system may include between one and a plurality of co-axially situated tubes. Each tube may be electrically connected to a power supply wherein a voltage may be applied thereto. Core-shell particles may be collected on a collection target, which may be a wet or dry collector, and electrically connected to the power supply. Core-shell particles and methods of manufacture are also disclosed. The precursors of the core-shell particles may be polymer- or biomacromolecule-based solutions and may include at least one treatment agent incorporated therein. The number of “core” particle(s) within the “shell” may vary and may provide different treatment agent release profiles depending on the material and/or chemical characteristics of the polymer and/or biomacromolecule used. Methods of treating a condition are also disclosed. A treatment may include delivery of a plurality of core-shell particles which include a treatment agent to a treatment site. Delivery may be performed by a surgical procedure or by a non-invasive procedure such as catheter delivery.
Gangliosides prodn. comprises (a) extracting mammalian nervous tissue at least one 1-4C alcohol and at least 1 non polar organic solvent, (b) filtering the mixt. and adding water to produce an aq. alcoholic phase, (c) absorbing gangliosides in the phase on an ion exchange material which is then washed with a ketone, (d) recovering the gangliosides using a solvent mixture including water, 1-4C alcohol(s), organic solvent(s) and alkali(s), (e) purifying the recovered material by partition or absorption column chromatography and (f) recovering the extracted gangliosides from the column. The nervous tissue is preferably bovine encephalic matter, spinal cord or cerebellum. In step (a), the 1-4C alcohol is isopropanol and the organic solvent is toluene, dichloromethane, chloroform, 1,2-dichloroethane or dichloroethylene. The ion exchange material is a dextran- or cellulose-based material applied at a ratio of 0.8-1.5 g for each 0.1 g of gangliosides to be absorbed. The ketone is acetone. The use of the obtained gangliosides is also claimed.
Part B Arm 1, an expansion cohort of up to 25 patients treated with single agent BI-1206 at the RP2D as determined in Part A Arm 1. Expansion to include a minimum of 12 chronic lymphocytic leukaemia (CLL) patients and six mantle cell lymphoma (MCL) patients.
The present invention relates to an algal extract-based composition for oro-dental use. This composition comprising a mixture of algae with at least  Ascophyllum nodosum  and  Fucus  spp. is characterized in that said mixture of algae has a proportion of  Ascophyllum nodosum  of at least 90% of the weight of the mixture and that the proportion of  Fucus  spp. is at most 10% of the weight of the mixture, and in that said extract is combined with a natural surfactant and/or with a zeolite or a mixture of zeolites. The present invention also relates to uses of said composition, in particular for dental prevention and/or care. Applications in the oro-dental field, both preventively and curatively.
Early innate immune responses play an important role in determining the protective outcome of Mycobacterium tuberculosis (Mtb) infection. Nuclear factor κB (NF-κB) signaling in immune cells regulates the expression of key downstream effector molecules that mount early antimycobacterial responses. Using conditional knockout mice, we studied the effect of abrogation of NF-κB signaling in different myeloid cell types and its impact on Mtb infection. Our results show that the absence of IKK2-mediated signaling in all myeloid cells resulted in increased susceptibility to Mtb infection. In contrast, the absence of IKK2-mediated signaling in CD11c+ myeloid cells induced early proinflammatory cytokine responses, enhanced the recruitment of myeloid cells, and mediated early resistance to Mtb. Abrogation of IKK2 in MRP8-expressing neutrophils did not affect disease pathology or Mtb control. Thus, we describe an early immunoregulatory role for NF-κB signaling in CD11c-expressing phagocytes and a later protective role for NF-κB in LysM-expressing cells during Mtb infection.
Obesity is a major health burden worldwide. Although bariatric surgery (BS) is recognized as an effective strategy for weight loss and comorbidities improvement, its impact on muscle strength and quality is still unclear. We aimed to examine postoperative changes in muscle strength and quality and their relationship with body mass index (BMI) changes among adults undergoing BS. To this end, we systematically searched the WoS, PubMed, EBSCO, and Scopus databases. The meta-analyses, which included 24 articles (666 participants), showed that BS reduces absolute lower-limb isometric strength (ES = -0.599; 95% CI = -0.972, -0.226; p = 0.002). Subjects who experienced a more significant reduction in BMI after BS also suffered a higher loss of absolute muscle strength. Similarly, absolute handgrip strength showed a significant decrease (ES = -0.376; 95% CI = -0.630, -0.121; p = 0.004). We found insufficient studies investigating medium- and long-term changes in muscle strength and/or quality after BS. This study provides moderate-quality evidence that BS-induced weight loss can reduce the strength of appendicular muscles in the short term, which should be addressed in management these subjects. More high-quality studies are needed to evaluate the impact of BS on muscle strength and the different domains of muscle quality in the medium and long term (registered on PROSPERO CRD42022332581).
BACKGROUND: In recent years, virtual reality (VR) technology has been widely used to support cancer patients with physical, emotional, and functional needs. This systematic review aimed to investigate the application of VR in the supportive care of cancer patients.
METHOD: This systematic review was conducted in 2024. In this study, various databases including PubMed, Web of Science, Scopus, the Cochrane Library, Ovid, IEEE Xplore, and ProQuest were searched, and quantitative, qualitative, and mixed-method studies which were in English and published up to 20th May 2024 were included. The keywords consisted of "virtual reality," "supportive care," and "cancer". Studies were assessed in terms of quality and risk of bias using standard tools, and results were analyzed and reported narratively.
RESULTS: A total of 33 articles were reviewed. VR interventions, primarily using fully immersive head-mounted displays, were associated with significant reductions in anxiety, pain, and fatigue. VR also improved mood, relaxation, and overall quality of life, and some studies noted enhanced vital signs such as heart rate and blood pressure. This technology could be used along with other medical interventions. Both patients and healthcare providers reported high level of satisfaction with VR, and appreciated its ease of use and therapeutic benefits. However, some technical barriers, like inadequate visual performance and realism, were reported.
CONCLUSION: VR demonstrates substantial potential benefits as a supportive care tool for cancer patients, effectively addressing their psychological, physiological, psychosocial needs. Despite technical challenges, high level of user satisfaction and benefits underscore the need for further research to optimize VR interventions in cancer care.
Eight doses levels have been selected for evaluation in the Part 1 of the study. Dose escalation decisions will be determined based on toxicities observed during the first cycle ( 21 days or 28 days).
Genomic advancements have yielded pivotal insights into hematological neoplasms, particularly concerning germline predisposition mutations. Following the WHO 2016 revisions, dedicated segments were proposed to address these aspects. Current WHO 2022, ICC 2022, and ELN 2022 classifications recognize their significance, introducing more mutations and prompting integration into clinical practice. Approximately 5-10% of hematological neoplasm patients show germline predisposition gene mutations, rising with risk factors such as personal cancer history and familial antecedents, even in older adults. Nevertheless, technical challenges persist. Optimal DNA samples are skin fibroblast-extracted, although not universally applicable. Alternatives such as hair follicle use are explored. Moreover, the scrutiny of germline genomics mandates judicious test selection to ensure precise and accurate interpretation. Given the significant influence of genetic counseling on patient care and post-assessment procedures, there arises a demand for dedicated centers offering specialized services.
This group will receive a Sleeve Gastrectomy combined with hiatal hernia repair. Hiatal Hernia repair consists of a peri-esophageal dissection proximal to the diaphragmatic crura to achieve an intra-abdominal esophageal length of 2-3 cm. The pillars will then be closed anteriorly and posteriorly using nonabsorbable sutures.
Novel compounds of formula <FORM:1045544/C2/1> in which R1 is hydrogen, R is an alkyl radical having 1-3 carbon atoms, and n is 2-4, and non-toxic salts thereof with an inorganic or organic base, are prepared (a) by treating compounds in which R1 is an arylmethyl or diarylmethyl radical, with catalytically activated hydrogen until substantially an equimolar amount of hydrogen has been taken up, or (b) subjecting a compound in which R1 represents a carboxylic acyl radical or an a -alkoxyalkyl radical in which the alky radical of the alkoxy substituent can be bound to the parent chain in the form of a ring, to solvolysis.  The 4 - alkyl - 1,2 - diphenyl - 3,5 - dioxopyrazolidine starting materials may be prepared by condensing the appropriate malonic acids with hydrazobenzene derivatives of Formula V <FORM:1045544/C2/2> These compounds in which R1 is alkyl or acyl may also be prepared by condensing a malonic acid dihalide with the appropriate hydrazobenzene, and those in which R1 is alkyl or a -alkoxyalkyl may be prepared by condensing di-alkyl esters or alkyl ester halides of a malonic acid with a hydrazobenzene derivative. The hydrazobenzene compounds may be produced by reducing the corresponding azobenzenes.  The starting materials may also be prepared by introducing the 4-alkyl radical into the analogous unsubstituted pyrazoline compounds, e.g. by condensation with a saturated or unsaturated aldehyde and reduction of the 4-alkylidene or 4-alkenylidene compound obtained.  Therapeutic compositions useful for the treatment of acute and chronic inflammatory diseases, and possessing antiphlogistic properties, which can be administered orally, rectally or parenterally, contain as active ingredient the compounds of the first formula above or salts thereof.
Hodgkin's lymphoma revealed by a medullary compression with a double primary vertebral localisation is extremely rare. We report the case of a boy in middle childhood who was presented with slow progression of medullary compression syndrome over 9 months, ultimately leading to paraplegia with loss of sphincter tone. The spinal MRI showed two tumour processes at T9 and L1 with epidural extension. An anatomical-pathological examination of the biopsy of the tumour mass, along with immunohistochemical analysis, confirmed the diagnosis of a lymphocyte-rich classic Hodgkin's lymphoma, stage IV according to the Ann Arbor classification. The therapeutic strategy was based on chemotherapy. This study aims to report a unique clinical presentation of Hodgkin's lymphoma in a paediatric patient and underscores the diagnostic challenges encountered in such an uncommon scenario.
The present invention relates generally to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. In particular, the invention relates to methods of using cells that secrete factors that down-regulate the expression of cell adhesion molecules in vascular endothelial cells. Downregulating expression of cell adhesion molecules may reduce leukocyte adhesion to endothelial cells and thereby reduce extravasation. The result is a reduction in inflammation. The cells are non-embryonic, non-germ cells with pluripotent properties. These may include expression of pluripotency markers and broad differentiation potential.
Beginning the first or second day of radiotherapy, patients receive oral glutamine twice daily, including the days that they do not receive radiotherapy. Patients continue on treatment throughout radiotherapy and continue 2 weeks postradiotherapy or until grade 3 diarrhea occurs. Patients are followed weekly for 4 weeks, then at 12 months, and then at 24 months after radiotherapy.
Multimorbidity, the presence of 2 or more chronic conditions in a person at the same time, is an increasing public health concern, which affects individuals through reduced health related quality of life, and society through increased need for healthcare services. Yet the structure of chronic conditions in individuals with multimorbidity, viewed as a population, is largely unmapped. We use algorithmic diagnoses and the K-means algorithm to cluster the entire 2015 Danish multimorbidity population into 5 clusters. The study introduces the concept of rim data as an additional tool for determining the number of clusters. We label the 5 clusters the Allergies, Chronic Heart Conditions, Diabetes, Hypercholesterolemia, and Musculoskeletal and Psychiatric Conditions clusters, and demonstrate that for 99.32% of the population, the cluster allocation can be determined from the diagnoses of 4-5 conditions. Clusters are characterized through most prevalent conditions, absent conditions, over- or under-represented conditions, and co-occurrence of conditions. Clusters are further characterized through socioeconomic variables and healthcare service utilizations. Additionally, geographical variations throughout Denmark are studied at the regional and municipality level. We find that subdivision into municipality levels suggests that the Allergies cluster frequency is positively associated with socioeconomic status, while the subdivision suggests that frequencies for clusters Diabetes and Hypercholesterolemia are negatively correlated with socioeconomic status. We detect no indication of association to socioeconomic status for the Chronic Heart Conditions cluster and the Musculoskeletal and Psychiatric Conditions cluster. Additional spatial variation is revealed, some of which may be related to urban/rural populations. Our work constitutes a step in the process of characterizing multimorbidity populations, leading to increased comprehension of the nature of multimorbidity, and towards potential applications to individual-based care, prevention, the development of clinical guidelines, and population management.
All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scan \& 1 after approx. 2 weeks of radiotherapy treatment.
Participants in this arm will be administrated with HPV vaccine. The immunization schedule is 0,1,6 months.
Gabapentin Capsules, USP are supplied as imprinted hard gelatin capsules containing 100 mg, 300 mg and 400 mg of gabapentin, USP.

The inactive ingredients are mannitol, pre-gelatinized starch and talc. The 100 mg capsule shell contains titanium dioxide. The 300 mg capsule contains FD&C Red 40, D&C Yellow 10 and titanium dioxide. The 400 mg capsule shell contains FD&C Red 40, D&C Yellow 10 and titanium dioxide.

Gabapentin, USP is described as 1-(aminomethyl) cyclohexaneacetic acid with a molecular formula of C H NO and a molecular weight of 171.24. The structural formula of gabapentin is: 9172

C H NO M.W. 171.24 9172

Gabapentin, USP is a white to off-white crystalline solid with a pK of 3.7 and a pK of 10.7. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25. a1a2
Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.